1. **Investigate the stability and bioavailability of the identified XOI peptides:** Conduct in vitro and in vivo studies to assess the stability and bioavailability of the identified XOI peptides in different physiological conditions, such as varying pH, temperature, and enzymatic environments. Evaluate their resistance to degradation and absorption in the gastrointestinal tract.


2. **Explore the structure-activity relationship of XOI peptides:** Synthesize and test a series of XOI peptides with different amino acid sequences and modifications to determine the key structural features responsible for their inhibitory activity. This information can guide the rational design of more potent and selective XOI peptides.


3. **Study the molecular mechanisms of XOI inhibition by the peptides:** Investigate the detailed molecular interactions between the XOI peptides and XO using techniques such as X-ray crystallography, nuclear magnetic resonance spectroscopy, and molecular dynamics simulations. Determine the binding site of the peptides on XO and elucidate the mechanisms by which they inhibit XO activity.


4. **Evaluate the potential synergistic effects of XOI peptides with other anti-hyperuricemic agents:** Explore the potential synergistic effects of the XOI peptides with other anti-hyperuricemic agents, such as allopurinol, febuxostat, and benzbromarone. Investigate whether combinations of these agents can achieve enhanced XOI inhibition and improved efficacy in reducing uric acid levels.


5. **Conduct clinical trials to assess the safety and efficacy of XOI peptides in humans:** Design and conduct clinical trials to evaluate the safety and efficacy of the XOI peptides in humans with hyperuricemia or gout. Determine the optimal dosage, frequency, and duration of administration, and assess the peptides' ability to lower uric acid levels, improve clinical symptoms, and prevent gout attacks.